Business Context and Reporting Period
Company: 111, Inc. (Nasdaq: YI)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: 111, Inc. is a Cayman Islands holding company operating primarily in China through PRC subsidiaries. It operates an integrated online and offline healthcare platform, including "1 Medicine Marketplace" (B2C retail) and "1 Pharmacy" (B2B wholesale). The company connects pharmaceutical companies, pharmacies, and consumers, offering products ranging from prescription drugs to health and wellness items, alongside value-added services like online consultations and supply chain solutions.
Key Financial Metrics (2025 vs. 2024)
| Metric | 2025 (RMB) | 2025 (US$) | 2024 (RMB) | Change |
|---|---|---|---|---|
| Total Net Revenues | 12,556,023 | 1,795,488 | 14,401,249 | -12.8% |
| Net Loss | (22,515) | (3,219) | (20,776) | -8.4% (Widened) |
| Operating Cash Flow | 119,142 | 17,036 | 263,016 | -54.7% |
| Cash & Equivalents (End of Period) | 510,967 | 73,067 | 462,289 | +10.5% |
| Short-Term Borrowings | 187,631 | 26,831 | 160,981 | +16.5% |
| Redeemable Non-Controlling Interests | 935,917 | 133,834 | 1,038,914 | -9.9% |
Note: US$ amounts are translated at the rate of RMB 6.9931 to US$1.00 as of December 31, 2025.
Material Changes vs. Prior Period
- Revenue Decline: Total net revenues decreased 12.8% to RMB 12.6 billion. This was driven by a 12.7% drop in B2B product revenues and a 14.5% drop in B2C product revenues. The decline is attributed to enhanced competition in the Chinese pharmaceutical market and a strategic transition to an asset-light model following the divestiture of three operating subsidiaries in Q3 2025.
- Profitability: The company recorded a net loss of RMB 22.5 million in 2025, compared to RMB 20.8 million in 2024. While operating costs decreased in line with revenue, the net loss margin widened slightly to 0.2% of revenue.
- Cost Reduction: Operating costs and expenses decreased 12.8% to RMB 12.6 billion. Notable reductions included Selling and Marketing expenses (-17.6%) and Technology expenses (-13.3%), reflecting cost-saving initiatives and reduced payroll.
- Cash Flow: Operating cash flow turned positive for the second consecutive year but decreased significantly to RMB 119.1 million from RMB 263.0 million in 2024, primarily due to changes in working capital (specifically a decrease in accounts receivable and an increase in accounts payable).
Guidance, Outlook, Risks, and Contingencies
- Going Concern Uncertainty: The independent auditor (Grant Thornton) has issued a "Going Concern" opinion. The company has an accumulated deficit and faces potential cash redemption obligations from redeemable non-controlling interest holders. Management plans to mitigate this through restructuring redemption obligations, securing bank facilities, and strategic capital restructuring.
- Redemption Obligations: As of December 31, 2025, RMB 1.1 billion is recorded as redeemable non-controlling interests and accrued expenses related to investors in 1 Pharmacy Technology. These investors have the right to request redemption if a proposed STAR Market listing is not completed. The company has reached agreements with investors to restructure these obligations into phased repayments.
- Regulatory Risks: The company faces significant risks related to PRC regulations, including the Holding Foreign Companies Accountable Act (HFCAA), cybersecurity reviews, data privacy laws (PIPL), and restrictions on foreign ownership in the healthcare sector. Changes in these regulations could materially impact operations or security value.
- Dividend Policy: The company has not paid dividends and does not plan to do so in the near future, intending to retain earnings for business expansion.
Key Facts for Investor Verification
- Redemption Liability Status: Verify the current status of the RMB 1.1 billion redemption obligation and the specific terms of the restructuring agreements with non-controlling interest holders.
- Going Concern Mitigation: Assess the sufficiency of the company's cash reserves (RMB 511 million) and undrawn credit facilities against its short-term liabilities and potential redemption triggers.
- Asset-Light Transition Impact: Monitor the long-term impact of the Q3 2025 divestiture of three subsidiaries on future revenue growth and margin expansion.
- Regulatory Compliance: Confirm ongoing compliance with PRC cybersecurity and data transfer regulations, as well as the status of any required filings with the China Securities Regulatory Commission (CSRC).
- Revenue Concentration: Note that 97.5% of revenue comes from the B2B segment; verify the stability of this customer base amidst competitive pressures.